---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-127439"
form_type: "8-K"
ticker: "ANVS"
cik: "0001477845"
company_name: "Annovis Bio, Inc."
filed_at: "2024-12-11T23:59:59+00:00"
generated_at: "2026-05-29T04:41:52.869342+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Annovis Bio enters $50M at-the-market equity distribution agreement with Oppenheimer

## Summary
- Agreement allows sale of up to $50M of common stock at-the-market through Oppenheimer & Co.
- Oppenheimer will receive 3.0% commission on gross proceeds; company also reimburses certain expenses.
- Company has no obligation to sell any shares and may suspend or terminate the agreement at any time.
- Shares will be issued under existing effective shelf registration statement (File No. 333-276814).
- Offering is effective December 11, 2024; sales subject to company instructions and market conditions.

## SEC filing metadata
- accession: 0001104659-24-127439
- form_type: 8-K
- ticker: ANVS
- cik: 0001477845
- company_name: Annovis Bio, Inc.
- filed_at: 2024-12-11T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1477845/000110465924127439/0001104659-24-127439-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1477845/000110465924127439/tm2430444d2_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-127439
- JSON: https://secwatch.observer/filing/0001104659-24-127439.json
- Plain text: https://secwatch.observer/filing/0001104659-24-127439.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.